JP6437444B2 - 医薬的組合せ - Google Patents

医薬的組合せ Download PDF

Info

Publication number
JP6437444B2
JP6437444B2 JP2015545170A JP2015545170A JP6437444B2 JP 6437444 B2 JP6437444 B2 JP 6437444B2 JP 2015545170 A JP2015545170 A JP 2015545170A JP 2015545170 A JP2015545170 A JP 2015545170A JP 6437444 B2 JP6437444 B2 JP 6437444B2
Authority
JP
Japan
Prior art keywords
compound
combination
inhibitor compound
melanoma
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015545170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501222A5 (enExample
JP2016501222A (ja
Inventor
デイル・ポーター
キャロライン・エメリー
ルジアン・タン
パドマジャ・イェラミリ−ラオ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016501222A publication Critical patent/JP2016501222A/ja
Publication of JP2016501222A5 publication Critical patent/JP2016501222A5/ja
Application granted granted Critical
Publication of JP6437444B2 publication Critical patent/JP6437444B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015545170A 2012-11-29 2013-11-26 医薬的組合せ Expired - Fee Related JP6437444B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US61/731,174 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US61/731,555 2012-11-30
US201361755520P 2013-01-23 2013-01-23
US61/755,520 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
JP2016501222A JP2016501222A (ja) 2016-01-18
JP2016501222A5 JP2016501222A5 (enExample) 2017-01-12
JP6437444B2 true JP6437444B2 (ja) 2018-12-12

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545170A Expired - Fee Related JP6437444B2 (ja) 2012-11-29 2013-11-26 医薬的組合せ

Country Status (16)

Country Link
US (1) US9446043B2 (enExample)
EP (1) EP2925366B1 (enExample)
JP (1) JP6437444B2 (enExample)
CN (1) CN104812415A (enExample)
AU (1) AU2013352379B2 (enExample)
BR (1) BR112015012497B1 (enExample)
CA (1) CA2892578C (enExample)
DK (1) DK2925366T3 (enExample)
ES (1) ES2669248T3 (enExample)
HU (1) HUE037618T2 (enExample)
NZ (1) NZ708802A (enExample)
PL (1) PL2925366T3 (enExample)
RU (1) RU2674995C2 (enExample)
TR (1) TR201806682T4 (enExample)
UA (1) UA115250C2 (enExample)
WO (1) WO2014085381A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
WO2022221586A1 (en) * 2021-04-15 2022-10-20 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor
GB202408598D0 (en) * 2024-06-14 2024-07-31 Edvince Ab Combination treatments
GB202408599D0 (en) * 2024-06-14 2024-07-31 Vasopharma Ab Combination treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
ES2122764T3 (es) 1995-11-20 1998-12-16 Lilly Co Eli Inhibidor de la proteina quinasa c.
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
CN1253449C (zh) * 2000-11-07 2006-04-26 诺瓦提斯公司 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
EP2246346B1 (en) 2005-07-11 2012-10-24 Novartis AG Indolylmaleimide derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
PL2925366T3 (pl) 2018-08-31
BR112015012497A2 (pt) 2017-07-11
JP2016501222A (ja) 2016-01-18
EP2925366B1 (en) 2018-02-21
US20150306101A1 (en) 2015-10-29
AU2013352379B2 (en) 2018-09-06
CA2892578A1 (en) 2014-06-05
TR201806682T4 (tr) 2018-06-21
EP2925366A1 (en) 2015-10-07
RU2015124954A (ru) 2017-01-11
BR112015012497B1 (pt) 2022-05-17
AU2013352379A1 (en) 2015-06-11
CA2892578C (en) 2021-01-12
RU2674995C2 (ru) 2018-12-14
HUE037618T2 (hu) 2018-09-28
BR112015012497A8 (pt) 2019-10-01
WO2014085381A1 (en) 2014-06-05
ES2669248T3 (es) 2018-05-24
NZ708802A (en) 2019-09-27
HK1215789A1 (en) 2016-09-15
UA115250C2 (uk) 2017-10-10
DK2925366T3 (en) 2018-06-06
CN104812415A (zh) 2015-07-29
US9446043B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
US20180185365A1 (en) Pharmaceutical Combinations
JP6675313B2 (ja) 組合せ医薬
US20160129003A1 (en) Pharmaceutical Combinations
JP6768682B2 (ja) メラノーマの処置に使用するためのアピリモド
JP2016501222A (ja) 医薬的組合せ
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181114

R150 Certificate of patent or registration of utility model

Ref document number: 6437444

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees